ET-01 in Subjects With Lateral Canthal Lines, LCL-210

Inclusion Criteria:

• able to understand and give written informed consent

• 25 - 65 years of age

• willing to have facial pictures/videos taken per protocol

• mild or less Crow's Feet wrinkles (IGA 0-2) "at rest"

• moderate to severe Crow's Feet (IGA 3-4) "on contraction"

• ability to correctly grade a series of Crow's Feet pictures

• moderate to severe Crow's Feet (SSA 3-4) "on contraction"

• have adequate vision without the use of eyeglasses to assess facial wrinkles in amirror (contact lenses are OK)

• willingness to refrain from the use of facial fillers, retinoids, botulinum toxins,laser treatments, or any product affecting skin remodeling or that might cause anactive dermal response during the course of the study

• female subjects of childbearing potential must have a negative urine pregnancy testand be non-lactating at the Baseline visit

• female subjects of childbearing potential must utilize one of the following methodsof birth control throughout the study: intra-uterine device (IUD), diaphragm, acondom, a spermicidal gel or foam, oral contraceptives (provided subject has beenutilizing this method for at least 3 months prior to Baseline and has not changedthe brand within this period), or patch, injectable, implantable, or vaginal ringcontraceptives. Subjects may also participate if they are surgically sterilized (tubal sterilization or hysterectomy) or are in menopause.

• subjects should be in good general health as determined by the Investigator and freeof any disease that may interfere with study evaluations or the InvestigationalProduct.

Exclusion Criteria:

• history of adverse reactions to any prior botulinum toxin treatments

• history of vaccination with botulinum toxin

• history of non-response to any prior botulinum toxin treatments

• any botulinum toxin treatment anywhere in the prior 6 months

• history of participation in ET-01-LCL-210 in previous Cohorts 1 or 2 at any time inthe past

• history of periocular surgery, brow lift or related procedures

• soft tissue augmentation or any procedures affecting the lateral canthal region inthe prior 12 months

• dermabrasion or laser treatment in the periocular region in the last 6 months

• topical prescription-strength retinoids in the prior 3 months to the treatment area

• application of any topical prescription medication to the treatment area within 14days prior to treatment

• subjects on clinically significant, concomitant drug therapy (See Section 5.3below).).

• present or history of neuromuscular disease, eyelid ptosis, muscle weakness orparalysis

• present or history of "dry eye"

• hemophilia, hemorrhagic disorder, hemostatic dysfunction or other blood clottingdisorders

• use of systemic aminoglycosides in the week prior to treatment application

• participation in another investigational drug trial or receiving any investigationaltreatment(s) within 30 days of Baseline

• alcohol or drug abuse within the past 3 years

• psychiatric disease interfering with the subject's ability to give informed consent

• refusal or inability to comply with the requirements of the protocol for any reason